Atea Pharmaceuticals shares are trading higher after Tang Capital Partners affiliate, Concentra, sent an acquisition proposal to the company with terms to acquire all of its outstanding common stock.
Portfolio Pulse from Benzinga Newsdesk
Atea Pharmaceuticals has received an acquisition proposal from Tang Capital Partners affiliate, Concentra, to acquire all of its outstanding common stock.
May 22, 2023 | 7:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atea Pharmaceuticals' stock is trading higher after receiving an acquisition proposal from Concentra, an affiliate of Tang Capital Partners.
Atea Pharmaceuticals' stock is likely to experience a short-term increase in price due to the acquisition proposal from Concentra. Investors may view this as a positive development, leading to increased demand for the stock and driving the price higher.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100